

Use of MCV4 Among Children 2-10 years

Amanda Cohn, MD
LCDR, USPHS

Advisory Committee on Immunization Practices
February 27th, 2008

Notice to Readers

- Introduction
- Burden of Disease
- Cost-effectiveness analysis
- Safety and immunogenicity of MCV4
- Programmatic Implications
- Recommendations
- Future Directions

ACIP Position

- ACIP does not recommend routine vaccination against meningococcal disease children aged 2-10 years at this time.
- Children aged 2-10 years at increased risk of meningococcal disease should be vaccinated with MCV4 according to the previously published recommendations*.

*CDC. Notice to Readers. MMWR. 2007;56 (48);1265-1266,

ACIP Recommendation

- If healthcare providers or parents elect to provide meningococcal vaccination to children in this age group, as for children at increased risk for meningococcal disease, MCV4 is preferred to MPSV4.

VOTE